Welcome to Our Laboratory

Our primary research interest is to develop effective, safe, and off-the-shelf cancer immunotherapy. Adoptive immunotherapy is an especially promising therapeutic approach as represented by recent success of chimeric antigen receptor (CAR)-engineered T cell therapy against hematologic malignancies. Our overarching goal is to cure cancer by using the immune system.

Professor Yuki Kagoya, M.D., Ph.D.

News

  • 2024.06.04　Research Associate newly joined.
  • 2024.04.26　Our research was published in Cell Reports Medicine.
  • 2024.04.01　Postdoc researchers and graduate students newly joined.
  • 2023.11.20　Our research was published in Nucleic Acids Research.https://www.keio.ac.jp/ja/press-releases/2023/11/22/28-154650/
  • 2023.08.17　Our review article was published in International Immunology.
  • 2023.03.31　Our website has been opened.
  • 2023.03.22　Our research was published in International Immunology.
  • 2023.03.11　Our review article was published in Inflammation and Regeneration.

Latest news